| Summary: | Xpert Breast Cancer STRAT4 is a RT-qPCR platform that studies the mRNA expression of <i>ESR1</i>, <i>PGR</i>, <i>MKI67</i> and <i>ERBB2</i>, providing a positive or negative result for each of these breast cancer biomarkers. Its concordance with immunohistochemistry (IHC) and in situ hybridization (ISH) has been previously demonstrated, but none of the previous works was focused on HER2-equivocal (2+) cases identified by IHC. Thus, we studied the concordance between IHC/ISH and STRAT4 results for 112 HER2 2+ IBC samples, using 148 HER2 0+, 1+ and 3+ (no-HER2 2+) samples for comparison. We found 91.3% accuracy for the determination of HER2 status globally, 99.3% for no-HER2 2+ samples and 80.7% for HER2 2+ samples. Regarding the other biomarkers, we obtained 96.4% accuracy for estrogen receptor, 84.1% for progesterone receptor and 58.2% for Ki67. Our results suggest that the use of <i>ERBB2</i> mRNA for the evaluation of HER2 2+ cases is not a reliable reflex method to assess the <i>ERBB2</i> amplification status.
|
|---|